Dear Doctor Armitage: I have asked to be added to the list of public cementers at the Oct. 27th meeting of the EPA Dioxin Review Panel so that I can remind the panel that the issues they are reviewing have been previously addressed by other groups and I have attached the 2007 Hercules petition to the US Supreme Court as an example. This amicus curiae brief was submitted on behalf of thirty one distinguished scientists (21 toxicologists) to request that EPA be required to justify using a linear extrapolation default rather than the threshold approach as recommended by the 2006 NAS/NRC report on the “Health Risks from Dioxin and Related Compounds” to establish the cancer potency factor for dioxin. John Doull
IN THE
Supreme Court of the United States

Hercules Incorporated,
   Petitioner,

v.

United States of America,
   Respondent.

On Petition for a Writ of Certiorari to the
United States Court of Appeals
for the Eighth Circuit

BRIEF OF AMICUS CURIAE INDEPENDENT
GROUP OF ESTEEMED SCIENTISTS JOHN DOULL,
M.D., PHD., DAVID L. EATON, PH.D., HENRY C.
PITOT, M.D., PH.D., GERALD N. WOGAN, PH.D.,
ET. AL. AND THE AMERICAN COUNCIL
ON SCIENCE AND HEALTH

MICHAEL STEPHEN MARCUS *
MICHAEL S. MARCUS PLLC
584 Innsbruck Avenue
Great Falls, VA 22066
(703) 759-7635

* Counsel of Record Counsel for Amicus Curiae
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TABLE OF AUTHORITIES</td>
<td>ii</td>
</tr>
<tr>
<td>INTERESTS OF THE <em>AMICI CURIAE</em></td>
<td>1</td>
</tr>
<tr>
<td>SUMMARY OF THE REASONS FOR GRANTING THE WRIT</td>
<td>8</td>
</tr>
<tr>
<td>REASONS FOR GRANTING THE WRIT</td>
<td>9</td>
</tr>
<tr>
<td>CONCLUSION</td>
<td>20</td>
</tr>
<tr>
<td>CASES</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Environmental Protection Agency, <em>Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds</em> (2003)</td>
<td>11</td>
</tr>
</tbody>
</table>
IN THE
Supreme Court of the United States

No. 06-865

HERCULES INCORPORATED,
  Petitioner,

v.

UNITED STATES OF AMERICA,
  Respondent.

On Petition for a Writ of Certiorari to the
United States Court of Appeals
for the Eighth Circuit

BRIEF OF AMICUS CURIAE INDEPENDENT
GROUP OF ESTEEMED SCIENTISTS JOHN DOULL,
M.D., PHD., DAVID L. EATON, PH.D., HENRY C.
PITOT, M.D., PH.D., GERALD N. WOGAN, PH.D.,
ET. AL. AND THE AMERICAN COUNCIL
ON SCIENCE AND HEALTH

INTERESTS OF AMICI CURIAE ¹

The Amici respectfully submit this brief in support of the
Petitioner’s request for a writ of certiorari. Specifically, the
Amici support the Petitioner with regard to its request that this

¹ Pursuant to Rule 37.6, amici certify that no counsel for any party
authored this brief in whole or in part. No persons other than the amici
curiae or their counsel made a monetary contribution to the preparation or
submission of this brief. Letters reflecting the parties’ consent to the
filing have been submitted to the Clerk.
Court entertain Question Number Two, “Whether the Environmental Protection Agency’s use of its cancer potency factor for dioxin is contrary to the Administrative Procedure Act, 5 U.S.C. § 553. . .”.

The Amici are world renowned leaders in the fields of toxicology, pharmacology, oncology, pathology, cancer molecular biology, carcinogenesis, cancer epidemiology, and cancer risk assessment. The Amici are interested in assuring that important science-based decisions be founded on accepted principles and biological concepts and that the weight of the scientific evidence be a determining factor in the decision-making process.

Gerald N. Wogan, Ph.D. is Emeritus Professor of Toxicology and Chemistry at the Massachusetts Institute of Technology (MIT). He was Director of the Division of Toxicology and Head of the Department of Applied Biological Sciences. He is a Member of the National Academy of Sciences and the Institute of Medicine. He has served on the National Institutes of Environmental Health Sciences (NIEHS) Advisory Council, the National Cancer Institute (NCI) Advisory Board, and the Science Advisory Board of the U.S. Environmental Protection Agency (EPA). Dr. Wogan was recently awarded the General Motors Research Cancer Foundation Mott Prize for his lifetime contributions to cancer cause and prevention.

David L. Eaton, Ph.D. is Associate Vice Provost for Research and Professor of Environmental and Occupational Health Sciences at the University of Washington. He is also Associate Director of the Fred Hutchinson Cancer Research Center. He was Associate Chairman of the Department of Environmental Health and Director of the Toxicology Program at the School of Public Health and Community Medicine, University of Washington. He was President of the Society of Toxicology. Recently, Dr. Eaton chaired the National Academy of Sciences/National Research Council
Committee on Assessment of the Health Implications of Exposure to Dioxins.

Herman N. Autrup, Ph.D. is Professor of Environmental Medicine at the Institute of Public Health, University of Aarhus. Formerly, he was Chief of the Carcinogen Macro-molecular Interaction Section of the National Cancer Institute Laboratory of Human Carcinogenesis. Dr. Autrup was President of the Federation of European Toxicological Societies (EUROTOX).

Leslie Bernstein, Ph.D. is Professor of Preventive Medicine and former Vice Provost for Medical Affairs at the Keck School of Medicine, University of Southern California and AFLAC, Inc Chair in Cancer Research at the USC/Norris Comprehensive Cancer Center. Dr. Bernstein was President of the Society for Epidemiologic Research and is a Member of the Board of Scientific Counselors for the National Cancer Institute.

Sir Colin Berry, M.D., Ph.D. is Professor Emeritus of Pathology, former Director of the Institute of Pathology, and former Dean of the London Hospital Medical College, University of London. He was President of the European Society of Pathology. Dr. Berry is a former Member of the Medical Research Council of Great Britain.

Joseph R. Bertino, M.D. is the Associate Director and Chief Scientific Officer of The Cancer Institute of New Jersey and Professor of Medicine and Pharmacology at the UMDNJ-Robert Wood Johnson Medical School. Previously, Dr. Bertino was Chairman of Molecular Pharmacology and Therapeutics at Memorial Sloan-Kettering Cancer Center. Prior to that appointment, he was Chief of Oncology and Chemotherapy and Director of the Yale Comprehensive Cancer Center. Dr. Bertino was President of the American Society of Clinical Oncology and the American Association for Cancer Research. He is the recipient of the American Cancer Society Medal of Honor.
Jim Bridges, Ph.D. is Research Project Leader in the Centre for Toxicology, Emeritus Professor of Toxicology and Environmental Health, and former Dean of Sciences at the University of Surrey. Dr. Bridges was the first President of EUROTOX and is former Chairman of the European Union Scientific Advisory Committee on Toxicity, Ecotoxicity and the Environment.

Patricia A. Buffler, Ph.D., M.P.H. is Professor of Epidemiology and Dean Emerita at the School of Public Health, University of California at Berkeley. She is a Member of the Institute of Medicine. She was President of the Society for Epidemiologic Research, American College of Epidemiology and International Society of Environmental Epidemiology, and was elected Chair of the Epidemiology Section of the American Public Health Association. Dr. Buffler is the recipient of the Visiting Scientist Award of the International Agency for Research on Cancer (IARC).

Daniel M. Byrd III, Ph.D. is Deputy Director of the Life Sciences Research Office, Inc. Dr. Byrd held a variety of positions at EPA, including in the Office of Chemical Control and the Carcinogen Assessment Group, and was Executive Secretary of its Science Advisory Board.

Peter C. Dedon, M.D., Ph.D. is Professor of Toxicology and Biological Engineering and Deputy Director of the Center for Environmental Health Sciences at MIT.

John Doull, M.D., Ph.D. is Professor Emeritus of Pharmacology and Toxicology at the University of Kansas Medical School. He was President of the Society of Toxicology and the American Board of Toxicology. Dr. Doull was a member of the EPA Science Advisory Board and chaired the Committee on Toxicology of the National Academy of Sciences/National Research Council.

Raymond N. DuBois, M.D., Ph.D. is Director of the Vanderbilt-Ingram Cancer Center and Professor of Molecular
Oncology at Vanderbilt University Medical Center. He serves on the Board of Scientific Advisors to the Director of the National Cancer Institute.

Ronald M. Evans, Ph.D. is Professor in the Gene Expression Laboratory and March of Dimes Chair in Developmental and Molecular Biology at the Salk Institute for Biological Studies. Dr. Evans is a Member of the National Academy of Sciences and the Institute of Medicine. He is the recipient of the Albert Lasker Award for Basic Medical Research, known as “America’s Nobel Prize”. He has also received the General Motors Sloan Award for Cancer Research, which is given for the most outstanding recent contribution in basic science related to cancer research.

Corrado Galli, ERT is Professor of Toxicology and Director of the Centre of Evaluation of Toxicological Risk at the University of Milan. He is President of EUROTOX and a member of the IARC Expert Group “Risk Assessment of Carcinogens and Mechanisms of Action”.

Robert Golden, Ph.D. is President of ToxLogic, LLC. Previously, he was Project Director for the National Academy of Sciences/National Research Council.

Frederick P. Guengerich, Ph.D. is Professor of Biochemistry and Director of the Center in Molecular Toxicology at the Vanderbilt University School of Medicine. He was a member of the Advisory Council to NIEHS.

A. Wallace Hayes, Ph.D. is Visiting Scientist in the Department of Environmental Health at the Harvard School of Public Health. Formerly, he was Professor and Director of Integrated Toxicology at Wake Forest University School of Medicine. Dr. Hayes is President-Elect of the American College of Toxicology and Secretary-General of the International Union for Toxicology. He was President of the Society of Toxicology and the Academy of Toxicological Sciences.
Kent R. Hornbrook, Ph.D. is Professor Emeritus and former Chair of the Department of Pharmaceutical Sciences at the University of Oklahoma Health Sciences Center. He was a member of the Halogenated Organics Subcommittee of the EPA Science Advisory Board.

David G. Kaufman, M.D., Ph.D. is Professor of Pathology and Biochemistry and Vice-Chair for Research Development at the University of North Carolina School of Medicine. Dr. Kaufman was President of the American Association of Pathologists, Federation of American Societies for Experimental Biology, and the Carcinogenesis Specialty Section of the Society of Toxicology.

Henry C. Pitot, M.D., Ph.D. is Professor Emeritus of Oncology, Pathology and Laboratory Medicine and former Acting Dean of the University of Wisconsin Medical School. He also was Director of the McArdle Laboratory for Cancer Research. He was President of the American Association of Pathologists and the Society for Experimental Biology and Medicine. Dr. Pitot was also Chairman of the President’s National Cancer Advisory Board and Chairman of the Board of Scientific Counselors for the National Toxicology Program.

Alan P. Poland, M.D. is former Professor of Oncology at the University of Wisconsin. Dr. Poland is a member of the Executive Committee of the National Toxicology Program and was a member of the National Academy of Sciences/National Research Council Binational Cooperative Study of Exposure to TCDD (Dioxin) Committee.

Karl K. Rozman, Ph.D. is Professor of Pharmacology, Toxicology, and Therapeutics at the University of Kansas Medical Center. He is also Head of the Section of Environmental Toxicology at the GSF-Institut für Toxikologie, Neuherberg, F.R.G.

Stephen H. Safe, D.Phil. is Professor of Veterinary Physiology and Pharmacology and Director of the Center for
Environmental and Genetic Medicine at Texas A&M University System Health Science Center.

Rolf Schulte-Hermann, Ph.D. is Head of the Division of Toxicology and Prevention and former Director of the Institute of Cancer Research at the Medical University of Vienna. He is Chairman of the Austrian Society of Toxicology and Council Member of the European Association of Cancer Research.

James A. Swenberg, D.V.M., Ph.D. is Professor of Environmental Sciences at the University of North Carolina School of Public Health, Professor of Pathology at the University of North Carolina School of Medicine and Member of the Lineberger Comprehensive Cancer Center. He was a member of NIEHS Board of Scientific Counselors, the IARC “Working Group on Mechanistic Considerations in the Molecular Epidemiology of Cancer”, and President of the Carcinogenesis Specialty Section of the Society of Toxicology.

Steven R. Tannenbaum, Ph.D. is Professor of Toxicology and Chemistry at MIT. He was Co-director of the Bioengineering and Environmental Health Division and Director of the Division of Toxicology. He is a Member of the Institute of Medicine. He was a member of the Board of Scientific Counselors to the Division of Cancer Etiology, National Cancer Institute.

B. Frank Vincent, Ph.D. served as President of the International Society of Regulatory Toxicology and Pharmacology (ISTRP) and was a member of the Toxicology Forum.

Nicholas J. Vogelzang, M.D. is Director of the Nevada Cancer Institute. He was Director of the University of Chicago Cancer Research Center. He was a member of the Board of Directors of the American Society of Clinical Oncology and the Board of Directors of the Association of American Cancer Institutes.
William J. Waddell, M.D. is Professor and Chairman Emeritus of the Department of Pharmacology and Toxicology at the University of Louisville.

Raymond L. White, Ph.D. is Professor and Vice Chair Director of the Ernest Gallo Clinic and Research Center at the University of California, San Francisco. Previously, he was Executive Director and Senior Director of Science at the Huntsman Cancer Institute and Chairman of the Department of Oncological Sciences at the University of Utah School of Medicine. He is a Member of the National Academy of Sciences and the Institute of Medicine. Dr. White is a recipient of the General Motors Cancer Research Foundation Mott Prize for his lifetime contributions to cancer cause and prevention.

Charles R. Wolf, Ph.D. is Director of the University of Dundee Biomedical Research Centre and Honorary Director of the Cancer Research UK Molecular Pharmacology Unit. Dr. Wolf is a member of the Board of Directors of the Association for International Cancer Research and a member of the Advisory Committee to the National Cancer Institute Laboratory of Human Carcinogenesis.

The American Council on Science and Health is a consumer education consortium whose members include hundreds of scientists and health professionals.

SUMMARY OF THE REASONS FOR GRANTING THE WRIT

The Amici believe that the Writ for Certiorari presents an important legal issue with regard to whether the Environmental Protection Agency can ignore the overwhelming scientific consensus in rendering pervasive regulatory decisions and whether it can avoid accountability and review of its actions. In arriving at the critical decision in its dioxin cancer management program, the cancer potency factor, the EPA disregarded well established principles of pharmacology
and molecular biology in adopting a linear, rather than a threshold-based risk model. The fact that the EPA has ignored the scientific consensus is clearly established by a recent report of the National Academy of Sciences/National Research Council. Moreover, the EPA has failed on numerous occasions to provide adequate scientific bases for rejecting this scientific consensus in favor of a threshold model. These failures dictate a need for this Court to determine whether EPA should be required to hold an APA hearing with all the procedural due process provided therein.

**REASONS FOR GRANTING THE WRIT**

As scientists interested in cancer risk management, we support the Petitioner’s Request for a writ of certiorari. Specifically, we ask this Court to grant the Writ on the issue as to whether the Environmental Protection Agency should be required to hold a hearing, pursuant to the Administrative Procedure Act, 5 U.S.C. § 553 (APA), on the dioxin cancer potency factor. This potency factor is key to formulating a science-based cancer risk management program.

We believe the writ poses an issue of exceptional importance. It presents the question whether the weight of the scientific evidence, as opposed to rigid adoption of a default principle or a particular philosophy, will be the basis for critical regulatory decisions that have a significant effect on us all.

The *Amici* believe that science should be in the forefront in these types of important regulatory and societal decisions. The *Amici* suggest to this Court that when there is a clear worldwide scientific consensus, as there is in this case, the consensus should be a key element in the decision-making process. In this instance, there has been no formal hearing. The worldwide scientific consensus has been ignored in favor of a default decision which even the EPA admits lacks a strong scientific foundation.
The Amici are concerned about the scientific, economic, and social consequences of a regulatory process that ignores the well-established scientific principles and avoids accountability and review of its actions.

The Amici have taken the extraordinary step of filing this brief in support of the Petitioner’s request because we believe that the overwhelming scientific evidence is contrary to the EPA’s adoption of a linear approach to modeling cancer risk when the chemical in question (in this case dioxin) is a promoter and causes cancer through a non-genotoxic receptor-mediated mechanism. For these kinds of chemicals, there exists a strong presumption that a threshold-based risk assessment is warranted. Absent overwhelming supporting evidence, the use of a purely linear-based model to calculate cancer risk, as EPA has done in this case, is scientifically indefensible.

Consistent with this presumption, The Joint FAO/WHO Expert Committee on Food Additives in its 2002 evaluation of dioxin’s toxicity concluded “that a tolerable intake could be established for TCDD on the basis of the assumption that there is a threshold for all effects, including cancer”. World Health Organization, Evaluation of Certain Food Additives and Contaminants (2002) pg. 141.

The consequences of the misuse of a linear-based model are significant. For example, the EPA in 1993, using the linear model, set the acceptable daily intake of dioxin at 6 fg/kg/day. The Canadian Health and Welfare Department, using a threshold model, set acceptable daily intakes at 10,000 fg/kg/day.

Amici do not ask this Court to evaluate the scientific merits. Nor do we ask this Court to weigh competing scientific principles. What we do ask is that this important scientific debate be the subject of a formal hearing under the APA, the decision be based on the weight of the scientific
evidence, and that the ruling be subject to the scrutiny provided by judicial review.

In December 2003, the EPA released a preliminary draft document titled *Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds*, referred to as the Reassessment. In its risk characterization of dioxin, the EPA made several statements with which we agree:

It is important that this characterization convey the current understanding of the scientific community regarding these issues, highlight uncertainties in this understanding, and specify where assumptions have been used or inferences made in the absence of data.

... Binding of dioxin-like compounds to a cellular protein called the aryl-hydrocarbon receptor (AhR) represents the first step in a series of events attributable to exposure to dioxin-like compounds, including biochemical, cellular, and tissue-level changes in normal biological processes. Binding to the AhR appears to be necessary for all well-studied effects of dioxin, but it is not sufficient in and of itself to elicit these responses.

... There is general agreement that the mode of TCDD’s carcinogenicity is as an AhR dependent promoter and proceeds through gene expression and/or a modification of the action of a number of receptor and hormone systems involved in cell growth and differentiation, such as the epidermal growth factor receptor and the estrogen receptor.

The *Amici* would like to provide the scientific information that would permit this Court to understand the significance of these statements. It should be noted that this science is not...
novel. The fundamental scientific principles and data have existed for more than twenty years.

First, let us address the question of what is a cancer potency factor.

Nearly all relevant cancer risk data from human epidemiologic studies and experimental animal bioassays reflect doses much higher than those typically experienced by humans from exposure to dioxin. In order to manage cancer risk at levels normally experienced by humans, there must be an extrapolation from the existing data to low level exposures. This extrapolation involves two critical decisions: (1) selecting a “point of departure” (POD), which corresponds to the lowest dose associated with observable adverse effects within the range of data, and (2) selecting the mathematical model used to extrapolate risk for typical human exposures that are well below the POD. These calculations lead to the cancer potency factor, which in turn dictates the important cancer risk management decisions.

Estimating risks below the POD requires making assumptions about how dioxin might cause cancer at the lower exposures. A linear mathematical model assumes that there is a proportional cancer risk at all levels of exposure above zero, regardless of how small the exposure. A threshold model projects that there is a level below which the exposure does not present a cancer risk.

Next, let us explore the significance of the fact that the mode of dioxin’s carcinogenicity is receptor-mediated, that is, dependent on the Ah receptor. First, we need to understand what is cancer.

Cancer is a group of more than one hundred diseases in which abnormal cells grow and spread unrestrained throughout the body. The dominant characteristic of cancer is uncontrolled cell growth resulting from loss of control over cell proliferation and cell survival. Cancer cells proliferate
excessively. They are no longer subject to most of the normal controls on cell growth.

Normal cells have multiple mechanisms to regulate their growth. They reproduce only when instructed to do so. Also, they undergo programmed cell death which occurs in an absolutely predictable pattern. Cancer cells, in stark contrast, violate this scheme. They become deaf to the usual controls on growth and follow their own internal agenda for reproduction. Cells replicate when they are supposed to be non-producing. Cells live when they are programmed to die.

What do receptors have to do with cancer? Normal cellular function is dependent on the cell’s ability to process signals that the cell receives from sources outside and inside the cell. Cells need to sense the appropriate time to grow, divide, migrate, differentiate, survive or die. Cells contain an elaborate system of proteins that enable the cell to respond to these signals. These proteins are called receptors. AhR is such a receptor. Once activated, these receptors initiate signalling pathways which determine the response of the cells. Aberrant activation of one or more of these pathways can lead to unregulated cell division and the formation of a tumor.

The sequence of events associated with the AhR receptor-mediated mechanism can be explained as involving (a) entry of the dioxin into the cells, (b) binding of dioxin to the Ah receptor, (c) binding of the receptor-dioxin complex to DNA recognition sites, and (d) overexpression of specific genes relating to cell proliferation and cell death.

Signals from outside the cell (including exogenous chemicals such as dioxin) are recognized by the receptors on or within the target cell. The signalling molecule, which is referred to as a ligand, binds to the receptor. Binding of a ligand to a receptor may convert the receptor from an inactive to an active form which then initiates a chemical response in
the target cell. Activation of a receptor, such as the Ah receptor by dioxin, in and of itself is not sufficient to produce a biological effect.

After a complex series of processes, the activated receptor may bind to a certain region of the DNA. The DNA is the permanent repository for the genetic information of the cell. The function of the DNA is to direct the activities of the cell, including cell proliferation and programmed cell death. The DNA directs these activities through the manufacture (synthesis) of a huge variety of proteins which determine the behavior of the cell. This is known as gene expression.

Under the right circumstances, the activated dioxin-AhR receptor complex can bind to specific regions of the DNA known as dioxin responsive elements, or DREs. Those responsive elements of the DNA can affect cell proliferation and cell survival. This binding can alter gene expression, resulting in abnormal cell growth and survival of cells that normally would be programmed to die.

This upregulation of gene expression in itself does not cause cancer. It can, however, “promote” an existing cancer-prone cell.

This receptor-mediated mechanism implies a series of thresholds. First, there must be a sufficient quantity of ligand to result in receptor activation. Second, the biological response of the receptor to the ligand is nonlinear. Third, a sufficient number of receptors must be activated in order to send a potent enough signal to affect gene expression and ultimately cell proliferation and cell survival. There are other thresholds involved in receptor-mediation.

As we stated earlier, EPA accepts the fact that dioxin’s carcinogenicity is receptor-mediated and proceeds through gene expression and/or a modification of the action of a number of receptor and hormone systems involved in cell growth and differentiation, such as the estrogen receptor.
Consequently, the science dictates that, at the very least, there is a strong presumption that dioxin’s carcinogenicity is subject to a threshold and that threshold concepts should be utilized in modeling its cancer risk. These principles have been confirmed through extensive study of the estrogen receptor referenced by EPA.

There is general acceptance that dioxin operates as a promoter. EPA has classified dioxin as a strong promoter in its 2003 Reassessment of TCDD. What does that designation tell us as to whether dioxin should be managed on the basis of a threshold or linear model?

There are two broad classes of chemical carcinogens: genotoxic chemicals and non-genotoxic chemicals. Genotoxic chemicals directly damage the DNA and thereby mutate the genetic code. These chemicals are classified as initiators.

Non-genotoxic chemicals do not damage the DNA and thereby do not cause mutations in the genetic code. Non-genotoxic chemicals interfere with gene expression and growth factor signalling, thereby affecting normal cell regulation and resulting in proliferation of unwanted cells or the presence of “anarchic” cells that should be eliminated. There is no dispute that dioxin is a non-genotoxic chemical.

Nor is there any dispute that dioxin is a promoter. Promoters do not begin the cancer process. Mutations to the DNA are at the heart of cancer induction. Promoters do not cause mutations to the DNA. Rather, they enhance the development of cancer by expanding the population of cells that carry mutations.

Cells with mutations grow at a faster rate than normal cells, resulting in the clonal expansion of the cells carrying the mutation. The more cells there are carrying the growth enhancing mutation and the more times they divide, the greater the chance they will go through other mutations, carrying those cells one more step along the road to becoming cancer cells.
It has been well accepted for more than twenty years that promoters of carcinogenesis are non linear and exhibit thresholds of biological response. Consequently, the recognition that dioxin is a strong promoter implies a significant threshold aspect to its carcinogenicity.

Fortunately, this Court has the benefit of a recent critique by the National Academy of Sciences/National Research Council of EPA’s 2003 Reassessment of TCDD. This critique was conducted by a committee of eighteen of our country’s leading experts in cancer risk assessment. The committee was chaired by David L. Eaton, who is a party to this Amicus Brief.

In 2004, EPA requested the NRC to create an expert committee to review its 2003 Reassessment. In response, the NRC appointed the above Committee. The Committee was charged to review, among other things, EPA’s modeling assumptions. The charge specifically requested that the Committee address the validity of the nonthreshold linear dose response model utilized by EPA in formulating its dioxin cancer potency factor.

After reviewing volumes of data, the Committee summarized its conclusions with regard to estimating dioxin’s cancer risk as follows:

Because nearly all data (both human epidemiologic studies and experimental animal bioassays) relevant to cancer risk are for doses much higher than those to which the general human population is typically exposed, analysts must extrapolate below the doses observed when estimating risks. This extrapolation depends on first fitting a dose response curve to the observed data from a given study and choosing a “point-of-departure” (POD), which corresponds to the lowest dose associated with adverse effects within the range of the data from the experiment or study.

...
This extrapolation must be based on assumption about how TCDD . . . might cause cancer. Thus, the selection of the type of mathematical model used to extrapolate below the POD is a critical decision in the cancer risk assessment process. In the 2003 Reassessment, EPA chose to extrapolate below the POD with a “linear” model which assumes that the biological response increases proportionally with the level of exposure starting at a dose of zero. Risk assessments based on this approach are generally higher than those based on alternative “non linear” assumptions, where the biological response does not vary proportionately with the dose.

After reviewing EPA’s 2003 Reassessment and additional scientific data published since completion of the Reassessment, the committee unanimously agreed that the current weight of scientific evidence of the carcinogenicity of dioxin is adequate to justify the use of non linear methods consistent with a receptor mediated response to extrapolate below the POD. [emphasis added] The committee points out the data from NTP [National Toxicology Program] released after EPA generated the 2003 Reassessment provide the most extensive information collected to date on TCDD carcinogenicity in test animals, and the committee found the NTP results to be compelling. The committee concludes that EPA should reevaluate dose-response relationships for TCDD . . . Specifically, the committee determines that the scientific evidence is consistent with receptor mediated responses and favor the use of a non linear model over the default linear assumption to extrapolate below the POD for dioxin-related cancer risk. [emphasis added]

The Committee offered several reasons for its conclusion that a non-linear threshold approach is appropriate for dioxin cancer risk management. First, the Committee found that there is insufficient evidence that dioxin has initiating activity. They further found that dioxin enhanced tumor development through tumor promotion and that the promoting activity is mediated through the activation of the Ah receptor. This in turn leads to a variety of changes to gene expression, including those relating to cell proliferation. The Committee went on to state, “There is general consensus in the scientific community that non-genotoxic carcinogens that act as tumor promoters exhibit non-linear dose response relationships, and that thresholds (doses below which the expected response would be zero) are likely to be present.” [emphasis added]. *Id* at pg. 122.

Second, the Committee stated that a fundamental concept in pharmacology is that receptor-mediated responses have non-linear dose relationships. “Response is a function of the number of occupied and activated receptors which typically exhibit steep dose response relationships.” *Id* at pg. 124.

Third, in its own 2005 cancer guidelines, EPA provides the following guidance on choosing between linear and non-linear extrapolation approaches: “a nonlinear approach should be selected when there are sufficient data to ascertain the mode of action and conclude that it is not linear at low doses and the agent does not demonstrate mutagenic or other activity consistent with linearity at low doses”. *Id* at pg. 125.

Fourth, the recent NTP (National Toxicology Program) dioxin bioassay data provide evidence of non-linearity.

In summation, both the biology and the extensive review by the NRC Committee, in the opinion of the *Amici*, strongly support the writ for certiorari and the requested relief—requiring the EPA to hold an APA hearing and to base its dioxin cancer risk management on accepted scientific
principles and data. The EPA itself has acknowledged in its 2003 Reassessment that it is important its dioxin cancer risk management be consistent with the current understanding of the scientific community. Unfortunately, EPA has failed to act in a manner consistent with this important pronouncement.

The NRC Committee also commented that the EPA should more thoroughly justify and communicate its bases for its approach to dose-response modeling. Specifically, they stated “the selection of the default linear extrapolation approach was one of the most critical decisions in the Reassessment, but the decision to use this approach was not supported by a scientifically rigorous argument. . .”. Id at pg. 196.

This criticism is not new. For example, in 1995 EPA’s Science Advisory Board published a report criticizing EPA’s failure to articulate and explain its reasons for its dioxin linear modeling approach. Moreover, the EPA in the 1990’s was repeatedly faulted for ignoring the scientific field of receptor technology. Among these critics was Amici Dr. Alan Poland who discovered the binding affinity relationship of dioxin to the Ah receptor. It should be noted that EPA has not altered its dioxin cancer potency factor since 1980 in spite of the many scientific advancements illuminating dioxin’s modes of carcinogenicity.

The Amici believe that this continuing deficiency is another reason for this Court to grant the writ of certiorari.
CONCLUSION

The petition for writ of certiorari should be granted.

Respectfully submitted,

MICHAEL STEPHEN MARCUS *
MICHAEL S. MARCUS PLLC
584 Innsbruck Avenue
Great Falls, VA  22066
(703) 759-7635

* Counsel of Record  
Counsel for Amicus Curiae

February 21, 2007
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation at time of signing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerald N. Wogan, Ph.D.</td>
<td>Massachusetts Institute of Technology (MIT)</td>
</tr>
<tr>
<td>David L. Eaton, Ph. D.</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Herman N. Autrup Ph.D.</td>
<td>University of Aarhus</td>
</tr>
<tr>
<td>Leslie Bernstein, Ph.D.</td>
<td>Keck School of Medicine</td>
</tr>
<tr>
<td>Sir Colin Berry, M.D., Ph.D.</td>
<td>London Hospital Medical College</td>
</tr>
<tr>
<td>Joseph R. Bertino, M.D</td>
<td>The Cancer Institute of New Jersey / Robert Wood Johnson Medical School</td>
</tr>
<tr>
<td>Jim Bridges, Ph.D.</td>
<td>University of Surrey</td>
</tr>
<tr>
<td>Patricia A. Buffler, Ph.D., M.P.H.</td>
<td>University of California Berkley</td>
</tr>
<tr>
<td>Daniel M. Byrd III, Ph.D.</td>
<td>Deputy Director of the Life Sciences Research Office, Inc.</td>
</tr>
<tr>
<td>Peter C. Dedon, M.D., Ph.D.</td>
<td>Massachusetts Institute of Technology (MIT)</td>
</tr>
<tr>
<td>John Doull, M.D., Ph.D.</td>
<td>University of Kansas Medical School</td>
</tr>
<tr>
<td>Raymond N. DuBois, M.D., Ph.D.</td>
<td>Vanderbilt-Ingram Cancer Center, Board of NCI</td>
</tr>
<tr>
<td>Ronald M. Evans, Ph.D.</td>
<td>Salk Institute for Biological Studies</td>
</tr>
<tr>
<td>Corrado Galli, ERT</td>
<td>University of Milan</td>
</tr>
<tr>
<td>Robert Golden, Ph.D.</td>
<td>ToxLogic, LLC</td>
</tr>
<tr>
<td>Frederick P. Guengerich Ph.D.</td>
<td>Vanderbilt University School of Medicine</td>
</tr>
<tr>
<td>A. Wallace Hayes, Ph.D.</td>
<td>Harvard School of Public Health</td>
</tr>
<tr>
<td>Kent R. Hornbrook, Ph.D.</td>
<td>University of Oklahoma Health Science Center</td>
</tr>
<tr>
<td>David G. Kaufman, M.D., Ph.D.</td>
<td>University of North Carolina School of Medicine</td>
</tr>
<tr>
<td>Henry C. Pitot, M.D., Ph.d.</td>
<td>University of Wisconsin Medical School</td>
</tr>
<tr>
<td>Alan P. Poland, M.D.</td>
<td>University of Wisconsin</td>
</tr>
<tr>
<td>Karl K. Rozman, Ph.D.</td>
<td>University of Kansas Medical Center</td>
</tr>
<tr>
<td>Stephen H. Safe, D. Phil</td>
<td>Texas A&amp;M System Health Science Center</td>
</tr>
<tr>
<td>Rolf Schulte-Hermann, Ph.D.</td>
<td>Medical University of Vienna</td>
</tr>
<tr>
<td>James A. Swenberg, D.V.M., Ph.D.</td>
<td>University of North Carolina School of Public Health</td>
</tr>
<tr>
<td>Steve R. Tannenbaum, Ph.D.</td>
<td>Massachusetts Institute of Technology (MIT)</td>
</tr>
<tr>
<td>B. Frank Vincent, Ph.D.</td>
<td>International Society of Regulatory Toxicology and Pharmacology (ISTRP)</td>
</tr>
<tr>
<td>Nicholas J. Vogelzang, M.D.</td>
<td>Nevada Cancer Institute</td>
</tr>
<tr>
<td>William J. Waddell, M.D.</td>
<td>University of Louisville</td>
</tr>
<tr>
<td>Raymond L. White, Ph.D.</td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>Christopher R. Wolf, Ph.D.</td>
<td>University of Dundee Biomedical Research Centre</td>
</tr>
</tbody>
</table>